KanonCure Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • 2ndary - Private

KanonCure General Information

Description

Developer of a personalized cancer treatment platform designed to provide patients with effective treatment for their specific cancer. The company's platform specializes in cell therapy research and drug discovery, bringing products related to the treatment, diagnosis, and prevention of severe liver disease, enabling patients to get effective and safe treatment methods by reducing the fibrous component of cirrhosis and promoting liver regeneration.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 86 Nishimachi
  • Tottori University Faculty of Medicine
  • Yonago, Tottori 683-8503
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 86 Nishimachi
  • Tottori University Faculty of Medicine
  • Yonago, Tottori 683-8503
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KanonCure Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Generating Revenue
1. Seed Round 25-Jul-2018 Completed Generating Revenue
To view KanonCure’s complete valuation and funding history, request access »

KanonCure Patents

KanonCure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3805383-A1 Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells Inactive 08-Jun-2018
EP-3805383-A4 Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells Inactive 08-Jun-2018
US-11866483-B2 Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells Active 08-Jun-2018
US-20210115112-A1 Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells Active 08-Jun-2018
WO-2019235362-A1 Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells Inactive 08-Jun-2018 C07K14/8146
To view KanonCure’s complete patent history, request access »

KanonCure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KanonCure FAQs

  • When was KanonCure founded?

    KanonCure was founded in 2016.

  • Where is KanonCure headquartered?

    KanonCure is headquartered in Yonago, Japan.

  • What is the size of KanonCure?

    KanonCure has 1 total employees.

  • What industry is KanonCure in?

    KanonCure’s primary industry is Drug Discovery.

  • Is KanonCure a private or public company?

    KanonCure is a Private company.

  • What is KanonCure’s current revenue?

    The current revenue for KanonCure is .

  • How much funding has KanonCure raised over time?

    KanonCure has raised $6.15M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process